Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Aug 24, 2026
Aveanna Healthcare (AVAH) +39% in 30 Days: What’s Behind the Strong Rally?

Aveanna Healthcare (AVAH) +39% in 30 Days: What’s Behind the Strong Rally?

Key Takeaways

  • Aveanna Healthcare (AVAH) climbed roughly 39% over the trailing 30 days, rising from about $9.45 to above $13.
  • The move was driven primarily by a stronger-than-expected second-quarter report and a raised full-year outlook announced August 13, 2026.
  • Every operating division grew, revenue rose 13.7% year over year, and adjusted EPS of $0.22 beat consensus estimates.
  • The stock reached a five-year high as management highlighted a California pediatric nursing rate increase and expanding preferred-payer agreements.
  • Over the broader quarter, the shares have advanced approximately 80% from late-May levels near $7.30.

Aveanna Healthcare (AVAH) Company Overview and Market Position

Aveanna Healthcare Holdings Inc. is a diversified home care platform serving medically complex, high-cost patient populations across the United States. The company operates through three segments: Private Duty Services (PDS), which provides private duty nursing and pediatric therapy; Home Health & Hospice (HHH), covering in-home skilled nursing and end-of-life care; and Medical Solutions, which supplies enteral nutrition and related products.

Aveanna's strategy centers on aligning clinical capacity with government payers and managed-care organizations that offer enhanced reimbursement or value-based arrangements. Investors follow the stock closely because of its exposure to rising demand for home and community-based care, its preferred-payer momentum, and its ability to convert reimbursement gains into caregiver capacity and patient volumes. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Stock Performance: 30 Days and the Broader Quarter

Over the last 30 days, AVAH shares climbed from a closing price of $9.45 on July 24, 2026, to roughly $13.16 by August 21, 2026, a gain of approximately 39%. The advance accelerated sharply after the company reported second-quarter results on August 13, when the stock jumped from around $9 to above $11 in a single session and continued higher into the mid-$13 range.

The quarterly trend is even more pronounced. From late-May levels near $7.30, the shares have risen approximately 80%, recovering from a brief pullback into the low-$6 range in early June before staging a sustained rally. The result is a multi-month uptrend in which the stock has set a five-year high.

What Drove AVAH Stock in the Last 30 Days

The primary catalyst was the company's second-quarter report. Aveanna posted revenue of $670.5 million, up 13.7% year over year, while net income rose to $40.3 million from $27.0 million a year earlier. Adjusted earnings per share of $0.22 exceeded consensus estimates of $0.17, and adjusted EBITDA increased 8% to $95.4 million. All three operating divisions expanded, led by 14.8% growth in Home Health & Hospice and 14.0% growth in Private Duty Services.

Management also raised full-year guidance, lifting the revenue outlook to more than $2.68 billion and the adjusted EBITDA outlook to more than $365 million. Investors responded to several forward-looking developments, including a California 2027 budget provision for a meaningful pediatric private duty nursing rate increase effective January 1, 2027, the addition of three preferred-payer agreements in Private Duty Services, and progress on the Family First Homecare acquisition integration. The shares reached a five-year high amid the announcement.

What Drove AVAH Stock Performance Over the Last Quarter

The quarterly rally reflects a broader shift in how the market values Aveanna's operating turnaround. After years of contending with caregiver shortages and reimbursement pressure, the company has demonstrated sustained organic growth across all three segments and improved profitability. The closing of the Family First Homecare acquisition in early June, a repricing of its credit facility, and a steady expansion of preferred-payer agreements across each division reinforced confidence in the growth strategy.

Institutional positioning has also strengthened, with the number of hedge funds holding the stock increasing during the quarter. The combination of raised guidance, rate-relief visibility in California, and improving caregiver capacity has supported a re-rating of the shares from single-digit to double-digit levels over the three-month period.

Key Factors to Watch Going Forward

Several factors are likely to shape AVAH's trajectory in the coming months. Investors will monitor final details from California's Medi-Cal department on the pediatric private duty nursing rate increase, expected before the end of September, along with any additional state rate enhancements from pending budget cycles. Wage pass-throughs to caregivers and their effect on Private Duty Services gross margin will be an important operational signal.

The pace of preferred-payer agreement additions across all three segments, the Family First integration timeline, and progress toward the company's leverage target of below three times also warrant attention. Macroeconomic factors such as labor market conditions and interest rates remain relevant given Aveanna's variable-rate debt. These elements will be central to evaluating whether the recent momentum can be sustained. From what I see, this is important because it could determine how durable the re-rating proves to be.

Exploring AI-Powered Trading Strategies

I’ve found Tickeron’s Trending AI Robots page useful when looking for additional context on market moves like this one. It highlights a curated selection of AI-powered trading bots drawn from a platform that offers hundreds of bots trading thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving traders a streamlined view of active strategies across the market. The featured bots vary in trading style, holding timeframe, and performance metrics, so investors can evaluate approaches that align with different risk profiles and objectives. Exploring the page can help traders identify automated strategies and tools worth monitoring alongside their own research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AVAH

AVAH in -2.94% downward trend, sliding for three consecutive days on October 06, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where AVAH declined for three days, in 247 of 284 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for AVAH moved out of overbought territory on September 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 21 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.

The Momentum Indicator moved below the 0 level on September 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AVAH as a result. In 80 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

AVAH moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AVAH crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 56%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVAH advanced for three days, in 202 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

AVAH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 162 of 172 cases where AVAH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. AVAH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.615) is normal, around the industry mean (208.195). P/E Ratio (10.071) is within average values for comparable stocks, (175.456). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.223) is also within normal values, averaging (2.688).

The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVAH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 4.84B. The market cap for tickers in the group ranges from 20.9K to 93.66B. HCA holds the highest valuation in this group at 93.66B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was 1%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 21%. OPCH experienced the highest price growth at 33%, while NIVF experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was -12%. For the same stocks of the Industry, the average monthly volume growth was -0% and the average quarterly volume growth was -9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 45
Price Growth Rating: 54
SMR Rating: 66
Profit Risk Rating: 87
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
AVAH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry HospitalNursingManagement

Industry
N/A
Address
400 Interstate North Parkway SE
Phone
+1 770 441-1580
Employees
32000
Web
https://www.aveanna.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.
Aveanna Healthcare (AVAH) +39% in 30 Days: What’s Behind the Strong Rally?